Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

The Quick Take
A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.
Ground Level News gathers headlines from public news feeds. This page shows a short summary only; the full article and all rights belong to CNBC.



